Literature DB >> 16259106

Caveolin-1 and 14-3-3 sigma expression in follicular variant of thyroid papillary carcinoma.

Yasuhiro Ito1, Hiroshi Yoshida, Chisato Tomoda, Takashi Uruno, Yuuki Takamura, Akihiro Miya, Kaoru Kobayashi, Fumio Matsuzuka, Yasushi Nakamura, Kennichi Kakudo, Kanji Kuma, Akira Miyauchi.   

Abstract

There are two prominent types of thyroid carcinoma, papillary carcinoma (PC) and follicular carcinoma (FC) arising from thyroid follicular cells, which have different biological characteristics. The follicular variant of papillary carcinoma (FVPC) has a structure similar to FC, although it is classified as a subtype of PC. We have previously demonstrated that caveolin-1, a major component of caveolae and an inhibitor of growth signal transduction, and 14-3-3 sigma, a regulator of the cell cycle and signal transduction, are frequently expressed in pure PC, but not in FC. In this study, we investigated these expressions in FVPC and FC. Caveolin-1 and 14-3-3 sigma were expressed in 96.2% and 92.3% of FVPC, respectively. However, almost all FC, with only a few exceptions, were negative for these findings, indicating that these proteins were more frequently expressed in FVPC than in FC (p < 0.0001). These findings suggest that caveolin-1 and 14-3-3 sigma positively or negatively regulate the development of FVPC but not that of FC, reflecting the difference of biological characteristics of these two types of carcinoma.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16259106     DOI: 10.1016/j.prp.2005.08.002

Source DB:  PubMed          Journal:  Pathol Res Pract        ISSN: 0344-0338            Impact factor:   3.250


  9 in total

1.  Three-gene molecular diagnostic model for thyroid cancer.

Authors:  Nijaguna B Prasad; Jeanne Kowalski; Hua-Ling Tsai; Kristin Talbot; Helina Somervell; Guennadi Kouniavsky; Yongchun Wang; Alan P B Dackiw; William H Westra; Douglas P Clark; Steven K Libutti; Christopher B Umbricht; Martha A Zeiger
Journal:  Thyroid       Date:  2012-01-26       Impact factor: 6.568

Review 2.  Lateral and mediastinal lymph node dissection in differentiated thyroid carcinoma: indications, benefits, and risks.

Authors:  Yasuhiro Ito; Akira Miyauchi
Journal:  World J Surg       Date:  2007-05       Impact factor: 3.352

3.  Histological heterogeneity of Ewing's sarcoma/PNET: an immunohistochemical analysis of 415 genetically confirmed cases with clinical support.

Authors:  Antonio Llombart-Bosch; Isidro Machado; Samuel Navarro; Franco Bertoni; Patrizia Bacchini; Marco Alberghini; Apollon Karzeladze; Nikita Savelov; Semyon Petrov; Isabel Alvarado-Cabrero; Doina Mihaila; Philippe Terrier; Jose Antonio Lopez-Guerrero; Piero Picci
Journal:  Virchows Arch       Date:  2009-10-17       Impact factor: 4.064

4.  Regulation of 14-3-3sigma expression in human thyroid carcinoma is epigenetically regulated by aberrant cytosine methylation.

Authors:  Geeta Lal; Lakshmi Padmanabha; Matthew Provenzano; Matthew Fitzgerald; Jamie Weydert; Frederick E Domann
Journal:  Cancer Lett       Date:  2008-04-25       Impact factor: 8.679

5.  Proteomic profiling of follicular and papillary thyroid tumors.

Authors:  Anastasios Sofiadis; Susanne Becker; Ulf Hellman; Lina Hultin-Rosenberg; Andrii Dinets; Mykola Hulchiy; Jan Zedenius; Göran Wallin; Theodoros Foukakis; Anders Höög; Gert Auer; Janne Lehtiö; Catharina Larsson
Journal:  Eur J Endocrinol       Date:  2012-01-24       Impact factor: 6.664

6.  Expression of caveolin-1 in tongue squamous cell carcinoma by quantum dots.

Authors:  J Xue; H Chen; L Diao; X Chen; D Xia
Journal:  Eur J Histochem       Date:  2010-04-14       Impact factor: 3.188

7.  Diagnostic and prognostic markers in differentiated thyroid cancer.

Authors:  José M Gómez Sáez
Journal:  Curr Genomics       Date:  2011-12       Impact factor: 2.236

8.  Expression of Caveolin-1 Is Associated With Thyroid Function in Patients With Human Papillary Thyroid Carcinoma.

Authors:  Jingyi Zhang; Dongxia Yan; Lianping He; Qing Zhang; Shuang Wen; Peiyu Liu; Hong Zhou; Yongde Peng
Journal:  Dose Response       Date:  2020-04-15       Impact factor: 2.658

Review 9.  Thyroid malignant neoplasm-associated biomarkers as targets for oncolytic virotherapy.

Authors:  Mingxu Guan; Yanping Ma; Sahil Rajesh Shah; Gaetano Romano
Journal:  Oncolytic Virother       Date:  2016-06-21
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.